5W Public Relations, the nation's fastest growing public relations agency in the U.S., announced today that BrainStorm Cell Therapeutics Inc. (OTCBB:BCLI), a highly advanced adult stem-cell research firm on the cusp of certain breakthroughs for neurological disorders such as Parkinson's, Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS), has hired the firm as its PR agency of record.
With its cutting edge, non-controversial stem cell research cultivating adult stem cells rather than embryonic tissue, BrainStorm is in advanced testing stages of animal and safety tests for exciting new treatments for Parkinson's Disease and preliminary research in Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's Disease, and its goal is to develop long-term and even permanent remedies for these life-threatening disorders.
By way of BrainStorm's research and treatments, those stricken with these diseases may finally see relief. Investors backing BrainStorm are trading in a company that is developing treatment to save lives, while it also provides an investment option and the potential for financial opportunity.
"We are extremely honored to work with BrainStorm," said Ronn Torossian, President & CEO, 5W Public Relations. "Raising awareness for the company and its cause could potentially help to save many lives, and given our depth of experience in the medical and research arena, as well as our staff's established media relationships in this area, we believe this is a perfect match."
"5W Public Relations is a firm with unmatched experience in harnessing media and developing unique strategy," said Chaim Lebovits, President of BrainStorm Cell Therapeutics Inc. "With substantial expertise in business media, and in the health and wellness areas, including work within our industry, 5W Public Relations is uniquely qualified to handle this innovative account. With Brainstorm's recent announcement of its $5 million equity financing arrangement, it is now able to accelerate its technology and business development efforts, including partnering with firms such as 5W Public Relations."
About 5W Public Relations
Headquartered in New York, with an office in Los Angeles, 5W Public Relations (www.5wpr.com), the nation's fastest growing independent PR firm for the past three years in a row (2004-2006), maintains practice areas specializing in bio-technology, corporate, health, consumer, entertainment, crisis communications, event management and public affairs. Described by a leading PR trade magazine as "aggressive in a way that clearly resonates with clients looking for a firm staffed with type A-plus personalities, a BS-free approach, and results from Day One," 5W's culture is aggressive, energetic, fast-paced and focused. The agency boasts a diversified client portfolio second to none, including: Evian Natural Spring Water, Anheuser Busch, NICE Systems, Phillips-Van Heusen Corporation, the world's largest shirt and neckwear company, VeriSign, Patina Restaurant Group, the nation's largest multi-concept restaurant group, The Ice Rink at Rockefeller Center, 530 store retail chain United Retail Group/Avenue Stores, Fannie Mae Foundation, Benny Hinn Ministries, The Language Access Network, Zone Chefs, The Pritikin Longevity Center & Spa, celebrities including Pamela Anderson, Snoop Dogg, Ice Cube, Nick Cannon and NBA Star Jalen Rose, a plethora of publicly traded technology companies, and a variety of other global interests, national corporations, high-profile individuals, regional businesses, government agencies and academic institutions. The agency was named "Boutique Agency of The Year" by a leading PR Trade Magazine.
About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is an emerging company developing adult stem cell therapeutic products, derived from autologous (self) bone marrow cells, for the treatment of neurodegenerative diseases. The NurOwn(TM) patent pending technology is based on discoveries made by the scientific team led by prominent neurologist Professor Eldad Melamed, Head of Neurology at Rabin Medical Center, and expert cell biologist Dr. Daniel Offen, Head of the Neuroscience Laboratory at the Felsenstein Medical Research Center of Tel-Aviv University. The technology allows for the differentiation of bone marrow-derived stem cells into functional neurons and astrocytes, as demonstrated in animal models. The Company holds rights to develop and commercialize the technology through an exclusive, worldwide licensing agreement with Ramot at Tel Aviv University Ltd., the technology transfer company of Tel-Aviv University. The Company's initial focus is on Parkinson's disease, although its technology has promise for treating several others diseases including MS, ALS, Huntington's disease and stroke.
Safe Harbor Statement
Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. The potential risks and uncertainties include, among others, risks associated with BrainStorm Cell Therapeutics Inc.'s limited operating history, history of losses and expectation to incur losses for the foreseeable future; dependence on key executives and on its scientific consultants; ability to identify, negotiate and successfully implement strategic partnering relationships; ability to complete clinical trials successfully and to obtain required regulatory approvals; competition with companies, some of which have greater resources and experience in developing and obtaining regulatory approval for treatments in BrainStorm Cell Therapeutics Inc.'s market; the limited public trading market for BrainStorm Cell Therapeutics Inc.'s stock which may never develop into an active market; and other factors detailed in BrainStorm Cell Therapeutics Inc.'s annual report on Form 10-KSB, quarterly reports on Form 10-QSB, current reports on Form 8-K and other filings with the Securities and Exchange Commission available at http://www.sec.gov/ or by request to the Company. The Company does not undertake any obligation to update forward-looking statements made by us.
